Experimental Model of Cardiotoxicity

Abstract

The occurrence of heart electrophysiology dysfunction or/and muscle damage is referred to as cardiotoxicity. The heart weakens and becomes less efficient at pumping and hence circulating blood. Cardiomyopathy can be caused by a variety of factors, including viral infections, diseases such as diabetes, ischemia, hypertension, obesity, radiation therapy, antipsychotic drugs, cytotoxic drugs, most notably chemotherapeutic agents; antitumor antibiotics, monoclonal antibodies, tyrosine kinase inhibitors, platinum-based compounds, microtubule inhibitors, vinca alkaloids, antimetabolites, proteasome inhibitors, topoisomerase inhibitors, alkylating agents, corticosteroids. This chapter focuses on the mechanisms of cardiotoxicity, animal models and transgenic methods used in studies, and the effects of therapeutic agents on cardiotoxicity.

Fabrication of Nanoformulation Containing Carvedilol and Silk Protein Sericin against Doxorubicin Induced Cardiac Damage in Rats

“…Cardiotoxicity is defined by cardiac dysfunctions, arrhythmia, hypotension, achypnoea, oedema, heart muscle injury, alterations in transmission pathways, and toxic effects on the heart [5]. Cardiomyopathy is characterized by muscle damage to heart tissues rendering the cardiac muscleincapable of efficient pumping leading to heart failure [6,7]. Cardiac hypertrophy is a compensatory response to volume or pressure stress, transmutations of sarcomeric and other proteins, or a decrease in contractile mass right before myocardial infarction.…”

Comparative Evaluation of Vehicle, Dose, and Duration-related Oxidative, Cardiotoxic, Inflammatory and Histologic Responses of Chromium 6+ and Doxorubicin in Rats’ Heart

“…Many studies have revealed that cardiotoxicity may occur due to exposure to drugs, toxic metals, and other unknown causes (Guven et al,2018). Cardiotoxicity results in myocardial and electrophysiology dysfunctions which affects the heart ability to pump blood e ciently resulting in various co-morbidities and deaths ( (Tabassum et al, 2015;Mladěnka et al,2018;Erbaş et al,2022). Doxorubicin, an established cardiotoxic agent, is a broad-spectrum antitumor drug used to treat various cancers but could lead to cardiac failure and cardiomyopathies even after treatment cessation ( (Hardaway, 2019;Abdelatty et al,2021;Morelli et al,2022).…”